Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review

Autor:	Alexander Egeberg, Mina Amin, Jeremy Man, Jashin J. Wu, Erica B Lee
Rok vydání:	2018
Předmět:	Adult Male medicine.medical_specialty Tuberculosis Adolescent Dermatology Severity of Illness Index Etanercept Young Adult 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Latent Tuberculosis Psoriasis Internal medicine Epidemiology Adalimumab Humans Medicine Child Aged Retrospective Studies 030203 arthritis & rheumatology Biological Products Latent tuberculosis Tuberculin Test Tumor Necrosis Factor-alpha business.industry Incidence Retrospective cohort study Middle Aged bacterial infections and mycoses medicine.disease Female business medicine.drug
Zdroj:	Journal of Dermatological Treatment. 29:671-675
ISSN:	1471-1753 0954-6634
Popis:	Although tuberculosis screening guidelines for psoriasis patients on TNF inhibitors exist, few studies have reported the prevalence of latent tuberculosis infection (LTBI) and conversion rates in this population.To determine the incidence of LTBI and active tuberculosis in patients with psoriasis receiving TNF inhibitor therapy.A total of 138 patients were included in our retrospective study of patients treated from September 2004 to September 2017. Tuberculin skin test was considered positive with an induration of greater than 5 mm. History of Bacillus Calmette-Guérin vaccination, follow-up tests and prophylaxis were recorded.Among 99 biologic-naïve patients, 14 had LTBI before starting biologic therapy and five developed LTBI during TNF inhibitor therapy. One biologic-naïve patient developed LTBI, then active tuberculosis. Among 39 non-biologic-naïve patients, three had LTBI before starting any biologic therapy, and one developed LTBI during treatment.Limitations include small sample size and limited information documented in the medical chart.LTBI appears to be prevalent among psoriasis patients. Screening for LTBI in patients on biologics may reduce risk of active tuberculosis; however, current methods may not be fully effective. Clinicians may need to use other tools including risk factor assessment to fully evaluate risk.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deea612b3acb72739bcfce94ffd346c7 https://doi.org/10.1080/09546634.2018.1443198 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.